19 results
Diabetic Peripheral Neuropathy - Pharmacotherapy

Peripheral neuropathy is a common microvascular complication of diabetes. In clinic patients
Diabetic Peripheral ... clinic patients should ... pregabalin as treatment ... #Pharmacology # ... Management #Medications
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
Comparison of anti-diabetic ... risks, and therapy should ... #pharmacology #pharmacotherapy ... table #comparison #management ... endocrinology #treatment
In 2018, opioid withdrawal should be considered a buprenorphine deficiency. Otherwise, a multitude of comparatively ineffective
opioid withdrawal should ... comparatively ineffective treatments ... @emupdates #Management ... #Pharmacology # ... #Alternatives #Dosing
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... treatment #medications ... #decisionaid #cardiology ... hematology #warfarin #dosing
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
Management of Diabetes ... initiation of treatment ... recommends, metformin should ... and CKD should ... evidence-based pharmacologic
Flowchart to diuretic use in acute heart failure.

(A) Congestion with volume overload. 

(B) Treatment algorithm after
(B) Treatment algorithm ... &Higher dose should ... administration, once a day dosing ... #HeartFailure #Cardiology ... #Management
Heart Failure (HFrEF) Treatment - GDMT for stage C 

For patients with Heart Failure with REDUCED
Failure (HFrEF) Treatment ... with HFrEF, we should ... HeartFailure #HFrEF #Pharmacology ... #Management #Treatment ... #StageC #Cardiology
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Management during ... Management during ... Management during ... started, patients should ... #cardiology #treatment
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... Patients should ... been shown non-inferior ... #semaglutide #Diabetes ... #Pharmacology #
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Individualized Treatment ... isolate DST result should ... Tuberculosis #MDRTB #management ... #regimens #pharmacology ... #dosing #idsa #